Document Detail

Endothelin-1 and hypertension: from bench to bedside.
MedLine Citation:
PMID:  18367029     Owner:  NLM     Status:  MEDLINE    
Endothelin-1 (ET-1) exerts a wide range of biologic effects that can influence systemic blood pressure. Recent studies indicate that increased activity of the ET system in the vasculature, with resultant activation of primarily ET A receptors, can contribute to hypertension. In contrast, decreased production of ET-1 in the renal medulla, and reduced activation of collecting duct ET B receptors, can also elevate systemic blood pressure. Both ET A and combined A/B receptor blockers reduce blood pressure in hypertensive patients. Several important questions remain with respect to the ET system in hypertension, including how ET receptor antagonists will interact with other antihypertensive agents, which receptor subtypes should be targeted, and what the effect of ET blockade will be on hypertension-related end-organ damage as opposed to blood pressure alone.
Donald E Kohan
Related Documents :
19327599 - Does treatment of hypertension decrease the incidence of atrial fibrillation and cardio...
12556669 - Optimal treatment of hypertension and cardiovascular risk reduction in african american...
17048439 - Transient cortical blindness during chemotherapy (pvb) for ovarian germ cell tumor.
15654709 - Interventions used to improve control of blood pressure in patients with hypertension.
12948429 - Isolated systolic hypertension and the risk of vascular disease.
16157079 - Should the target for blood pressure control specify both a systolic and a diastolic co...
15954959 - Positive end-expiratory pressure improves arterial oxygenation during prolonged pneumop...
22947359 - Ambulatory blood pressure monitoring in patients with chronic kidney disease and resist...
3553479 - Potassium-rich and sodium-poor salt reduces blood pressure in hospitalized patients.
Publication Detail:
Type:  Journal Article; Research Support, N.I.H., Extramural; Review    
Journal Detail:
Title:  Current hypertension reports     Volume:  10     ISSN:  1534-3111     ISO Abbreviation:  Curr. Hypertens. Rep.     Publication Date:  2008 Feb 
Date Detail:
Created Date:  2008-03-27     Completed Date:  2008-05-06     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  100888982     Medline TA:  Curr Hypertens Rep     Country:  United States    
Other Details:
Languages:  eng     Pagination:  65-9     Citation Subset:  IM    
Division of Nephrology, University of Utah Health Sciences Center, 1900 East 30 North, Salt Lake City, UT 84132, USA.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Blood Pressure*
Endothelin-1 / metabolism*
Endothelins / antagonists & inhibitors
Hypertension / metabolism,  physiopathology*
Receptor, Endothelin A / metabolism
Receptor, Endothelin B / metabolism
Grant Support
Reg. No./Substance:
0/Endothelin-1; 0/Endothelins; 0/Receptor, Endothelin A; 0/Receptor, Endothelin B

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Tetrahydrobiopterin.
Next Document:  Angiotensin-converting enzyme 2: possible role in hypertension and kidney disease.